Operationalizing ADC Clinical Trials: Best Practices for Success 

January 29th, 2026
11 a.m. EST

As the oncology landscape evolves, antibody–drug conjugates (ADCs) have emerged as one of the most promising modalities in targeted cancer therapy. With 15 ADCs approved globally and more than 400 in development, the opportunity to advance patient outcomes has never been greater1. Yet, success in ADC trials requires a deep understanding of the safety profile and the operational complexities that accompany these transformative therapies. 

This webinar will explore strategies to optimize ADC clinical trial execution. Attendees will learn how to design protocols geared toward dose optimization by applying Project Optimus principles, navigate global site selection, and implement appropriate site training with ADC-specific patient education and toxicity management tools. The session will also highlight how biomarker-driven enrollment, streamlined screening, toxicity management, and reduced procedural burden can enhance recruitment and retention while improving overall patient experience. 

Register today and join us for an in-depth discussion on operational excellence in ADC trials to shape the future of oncology research. 

Attendees will gain insights into: 

• The ADC therapeutic landscape and pipeline
• Global site selection, preparedness, and training required for successful ADC development 
• Dose optimization and safety monitoring, including capturing long-term outcomes 
• Incorporating the patient voice into protocol development and feasibility assessments for ADC therapies 

Registration Coming Soon  

Sources: 

1. Wang, R., Hu, B., Pan, Z. et al. Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol 18, 51 (2025). https://doi.org/10.1186/s13045-025-01704-3 

Speakers:

Ashley Herrick, PhD – Vice President, Oncology Program Strategy

Jordan Curry – Senior Project Director, Oncology